Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT01920191 | Phase I/II Trial of IMA950 Multi-peptide Vaccine Plus Poly-ICLC in Glioblastoma | PHASE1 | COMPLETED | 19 | — | — | Aug 1, 2013 | Mar 1, 2016 | Apr 20, 2016 | 1 | Switzerland |
| Arm | Type | Description |
|---|---|---|
| IMA 950 and Poly ICLC | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| IMA 950 | BIOLOGICAL | - |
| Poly ICLC | BIOLOGICAL | - |
| Immunomonitoring | OTHER | Blood samples, DTH analysis |
Inclusion Criteria: 1. Histological documentation of glioblastoma. For experimental purposes only, 5 additional grade III astrocytoma may be included (these cases will not be included in the endpoints analysis). 2. Patients must have completed radiation therapy with concomitant temozolomide. 3. HLA...